FILANA THERAPEUTICS, INC. 8-K

What Happened
Filana Therapeutics, Inc. (NASDAQ: FLNA) filed an 8‑K on June 15, 2026 reporting that its stockholders approved Amendment No. 2 to the company’s 2018 Omnibus Incentive Plan. The amendment increases the plan share pool, extends the plan term, adds anti‑repricing protections, and reduces certain annual award limits for directors and individuals.

Key Details

• Authorized shares increased by 4,000,000, from 5,000,000 to 9,000,000 shares under the 2018 Plan.
• Plan term extended by two years, now running through January 31, 2030.
• Amendment explicitly prohibits repricing, replacing, or cash‑out of stock options or SARs without stockholder approval.
• The amendment lowers the maximum annual compensation limits for non‑employee directors (expressed in both shares and dollar value) and reduces the maximum annual equity award limit per individual.

Why It Matters
This change gives Filana more shares to grant as equity compensation, which can help attract and retain employees and advisors but may increase potential dilution for existing shareholders. The extension to 2030 ensures the company can continue granting awards under the plan for a longer period. The anti‑repricing provision and lowered director/equity caps are governance features that limit certain dilutive actions and align with shareholder protections. For full details, see the related proposal in the company’s proxy materials referenced in the 8‑K.